Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07358962
Starting soon Observational

Mild Cognitive Impairment and Psychopathology

NCT07358962 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Phase
Observational
Started
2026-01-12
Last updated
2026-01-22

Condition(s) studied

Mild Cognitive Impairment (MCI)

Study summary

Mild Cognitive Impairment (MCI) is a condition characterized by cognitive deterioration greater than what is expected from normal aging, representing an important risk factor for the development of dementia. Early assessment of cognitive functions is therefore essential for promptly identifying any signs of decline. In addition to cognitive aspects, it is equally important to consider the possible psychopathological profile of patients, as such disorders can significantly influence the progression of the disease, quality of life, and the ability to manage daily activities. This protocol aims to explore the presence of psychopathological disorders in patients with MCI, with particular attention to their impact on awareness of cognitive deficits (anosognosia) and on the subjective perception of difficulties in daily life, especially in social and work contexts. The study seeks to outline a comprehensive picture of the psychopathological profile in patients with MCI, facilitating the identification of targeted and personalized interventions capable of improving clinical management and the overall well-being of the individual.

Eligibility

Sex
ALL
Min age
50 Years
Max age
72 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 50 and 72 years; * Diagnosis of Mild Cognitive Impairment (MCI), with referral to the Neuropsychology clinic for an initial evaluation or for clinical monitoring; * Absence of behavioral, psychiatric, or sensory disorders that could significantly compromise the performance of cognitive tests or the completion of questionnaires. Exclusion Criteria: * Neurological disorders other than MCI, such as recent stroke, severe traumatic brain injury, epilepsy, multiple sclerosis, or other atypical neurodegenerative diseases; * Major psychiatric comorbidities not stabilized at the time of the assessment (e.g., schizophrenia, bipolar disorder in an active phase, untreated severe depression); * Severe uncorrected sensory deficits (visual or hearing) capable of compromising the validity of cognitive and functional assessments; * Use of medications with significant potential cognitive impact (e.g., sedatives, high-dose antipsychotics) not stabilized at the time of the assessment; * Terminal-stage internal or oncological diseases, or other medical conditions that significantly interfere with the assessment procedures.

Primary outcome measure(s)

  • Prevalence of psychopathological disorders in patients with MCI — 12 months
    The primary outcome variable is the presence of psychopathological disorders, assessed using the MMPI-3 test, which is used as an indicator of the psychopathological profile in patients with mild cognitive impairment.

Trial sites (1)

FacilityCityRegionStatus
Irccs Centro Neurolesi Bonino Pulejo Messina Me

More IRCCS Centro Neurolesi Bonino Pulejo trials in Italy

New Technological Pathway for Gait Rehabilitation Starting soon
Eye-tracking Technology for Severe Communication Disability Recruiting
Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders Recruiting
Psychopathology in Adolescence Enrolling by invitation
Virtual Reality-supported Language Intervention for Preschool Children With DLD Enrolling by invitation

Other trials for the same condition

Exercises for Rehabilitation of COgnition and Lifestyle Enhancement in Patients With Mild Cognitive Impairment Recruiting
InRAD Observational Study Recruiting
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia Recruiting
Digital Solutions for Predicting the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors Recruiting
Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07358962 on ClinicalTrials.gov ↗ ← All trials in Italy